News
Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.
Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.
The inaugural Outsourcing in Clinical Trials & Clinical Trial Supply China conference will gather experts to discuss China's rapidly evolving clinical research landscape.
The US FDA has cleared Starlight Therapeutics' IND for a Phase Ib/IIa trial assessing the combination of STAR-001.
Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials. The Danish pharma said that the Phase II trial of coramitug (PRX004), an mAb ...
A rise in gonorrhea infections had been predicted, but if the vaccine reaches vulnerable populations, these are now expected to decline.
Urogen's Zusduri is the first non-surgical therapy to be approved for NMIBC, setting a new standard for the indication.
HMNC said a genetic subgroup of MDD patients benefited more from BH-200 in the Phase II trial, prompting Phase III plans.
Purespring Therapeutics has secured approval for its UK clinical trial application (CTA) for a Phase I/II trial of its lead programme, PS-002.
Topline results of a Phase II trial reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.
The World Health Organization (WHO) estimates that by early 2024, over 1,400 healthcare facilities that were previously active in global clinical trials. had been damaged or destroyed in the conflict.
The US FDA has approved Anbogen Therapeutics’ IND application for the oral HDAC1/2/3 inhibitor ABT-301 in preparation for a Phase I/II trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results